CELLmeric is a CUHK spin-off biotech company based on a core innovation “Virus-Free Gene Delivery System”, which highly preserve the genomic integrity and viability of the produced cells due to our low energy-based gene engineering platform.
We have successful generated safe and effective CAR-T cells with stable gene modification and superior anticancer activity; providing the first-in-class cell therapy for cancer, inflammatory diseases, and beyond.

By using our patented low energy gene delivery system, we can mass produce safe and effective
CAR-T/NK cells for immunotherapy without the use of virus.

2025:
Gold Medal in Asia Exhibition of Innovations and Inventions (Hong Kong)
Best Innovation Award in Shanghai Hong Kong Innovation Project Award 2025
Second prize in CUHK Entrepreneurship Competition 2025
Winner of the 2025 National Disruptive Technology Innovation Competition
Winner of START-UP EXPRESS (HKTDC)
Silver Medal in Inventions Geneva 2025 (Swiss)
2024:
Gold Prize of China International College Students’ Innovation Competition 2024
Silver Medal in Inventions Geneva 2024 (Swiss)
2023:
Bronze Medal in the 13th IIFME – International Invention Fair of the Middle East
2022:
Bronze Medal in the Inventions of Geneva 2022 (Switzerland)
2021:
Gold Medal with Congratulations of the Jury Medal in Inventions Geneva 2021 (Switzerland)
7th Youth Dream Makers 2021 (Hong Kong)
Unit 501, 5/F, Belgian Bank Building, 721-725 Nathan Road, Mongkok
CELLmeric Limited
Copyright © 2026 CELLmeric - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.